Blog / Archives
Illumina Guidance Drags Down Life Science Tools Sector: Maintain Caution
Dog Days of Summer Lie Ahead- Q3 Seasonality in Life Sciences is Weak A vicious 16% sell-off in Illumina Inc. (ILMN $58.43) due to revised 2011 guidance and subsequent analysts' reduced outlook....
QQQ Still Outperforming IBB and XBI in Vicious Sell-Off
Weakness in tools such as ILMN ($59.30) down 15% is hurting biotech. Also our mid cap biopharma index is down 2.5% . So the NASDAQ-100 is favored due to the inclusion of AAPL, AMZN, INTC and MSFT...
QQQ Trade Beats Biotech ETF’s after One Week
Last week we recommended that bulls trade the QQQ rather than pure biotech with ETF's such as IBB. The strategy was based on the outperformance of biotech compared to tech given that the Q's also...
Biotech Profit Taking Picks Up: MO Stocks Take A Hit-Caution
The Rayno Life Science Portfolio was down 1.76% today which in itself is not alarming but given the weekly volatility against a back-drop of macro issues it is time to avoid complacency. Let's...
Debt Negotiations Stall Market;Gold Up $15 at $1615
Note: we will return from vacation this week and focus on companies attending the AACC (American Association of Clinical Chemistry)Meeting in Atlanta this week). Market Down 0.5% as Both Parties...
Surprise Rally Takes Everything Up:Technology OutPerforms Biotechnology
Life Science Stocks Follow NASDAQ Up: EXAS, MITI, REGN Soar Large healthcare companies report over next two weeks Stocks roared today on IBM earnings last night, debt ceiling negotiation progress...
Bulls Better Off with QQQ than Pure Biotech for Now
With the QQQ you are still Bullish on Biotech We mentioned yesterday that those wanting to be bullish large cap NASDAQ stocks but remain bullish on biotech would be better off with a QQQ position as...
Life Science Stocks In Third Day of Sell-Off
Todays' Movers : CSII and IMGN Life Science and Drug stocks hit their third day of selling about 4% off July highs but 6% higher than June lows. The bellwether ETF IBB remains 6% above intermediate...
Review of Life Science Funds and ETF’s up 15% YTD
Edited Version Published in Investor Uprising June 2011 :Updated here JY 16, 2011 Biotechnology Has Outperformed the S&P Over Five Years Medical science has always been an important area for...
Sector Watch: Energy on Fire,Techs Strong,Healthcare a Bit Weak
Large cap drug and biotech stocks sold off as buyers favor technology. Within the NASDAQ-100 up 1% led by GOOG, BIDU and SIRI. Alexion (ALXN $52.19) bucked the weakness in biotech up 1.74% but GILD,...